HY072808 / Hefei Yigong Pharmaceutical - LARVOL DELTA

To evaluate the safety and efficacy of HY-072808 ointment at different concentrations in adults with mild to moderate atopic dermatitis, a multicenter, randomized, blinded, excipient-parallel protocol was used, phase II controlled clinical trial (ChiCTR) - P2 | N=138 | Completed | Sponsor: Peking University People's Hospital; China-Japan Friendship Hospital; Hefei Institute of Pharmaceutical Industry Co., Ltd.

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HY-0728-08 Cream in Treating Mild to Moderate Patients with Atopic Dermatitis (ChiCTR) - P1 | N=20 | Completed | Sponsor: The Second Affiliated Hospital of Anhui Medical University; Hefei Institute of Pharmaceutical Industry Co.,Ltd.

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Preclinical pharmacokinetic investigation of the bioavailability and skin distribution of HY-072808 Ointment, a novel drug candidate for the treatment of atopic dermatitis, in minipigs by a newly LC-MS/MS method. (PubMed, Xenobiotica) - "The distribution of HY-072808 ointment among different cortical layers in minipigs was studied for the first time. Following transdermal application of 2% HY-072808 ointment, the concentration in plasma and skin tissues in the order of epidermis > dermis > subcutaneous tissue ≈ subcutaneous muscle ≈ plasma; at 48 hours after the administration, the epidermis and dermis still had a high concentration of the drug."

Journal • PK/PD data • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology